Synthesis of potent and selective inhibitors of human plasma kallikrein.

Bioorg Med Chem Lett

Corporate Research Division, Miami Valley Laboratories, The Procter & Gamble Company, Cincinnati, OH 45253-8707, USA.

Published: February 1999

The synthesis and in vitro enzyme inhibition profile of a series of novel trifluoromethylketone (TFMK) inhibitors of human plasma kallikrein (PK) are described. We have developed an efficient method for the construction of peptide TFMKs that provides the final product devoid of compromised stereochemical integrity. Many of these compounds are potent inhibitors of PK and exhibit reduced inhibition of tissue kallikrein (TK) and plasmin (HP).

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(98)00562-9DOI Listing

Publication Analysis

Top Keywords

inhibitors human
8
human plasma
8
plasma kallikrein
8
synthesis potent
4
potent selective
4
selective inhibitors
4
kallikrein synthesis
4
synthesis vitro
4
vitro enzyme
4
enzyme inhibition
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!